Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about DAIICHI SANKYO COMPANY, LIMITED
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/18DAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
09/18Daiichi Sankyo Company, Limited and AstraZeneca Announce Reduction of Risk of Disease P..
CI
09/18Daiichi Sankyo Company Demonstrated Robust and Durable Tumor Response of 54.9% in Patie..
CI
09/17Daiichi Sankyo Company, Limited and Sarah Cannon Research Institute, LLC Announce DS-73..
CI
09/16Daiichi Sankyo Company, Limited and AstraZeneca Announces That the First Patient Was Do..
CI
08/30Daiichi Sankyo Company, Limited Announces Results from the Multinational, Randomized, C..
CI
08/10DAIICHI SANKYO : Enhertu significantly improved progression-free survival in DESTINY-Breas..
AQ
08/09ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Significantly Improved Progression-Free Surv..
CI
08/09DAIICHI SANKYO : ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Brea..
BU
07/30DAIICHI SANKYO : Consolidated Financial Results for the First Three Months of the Year End..
PU
07/30DAIICHI SANKYO : Top Management Presentation
PU
07/30DAIICHI SANKYO : Reference Data
PU
More most relevant news
All news about DAIICHI SANKYO COMPANY, LIMITED
09/21Nikkei 225 Falls 2.2% on China Property Outlook
MT
09/20Japanese shares fall on Evergrande jitters; bargain-hunting limits losses
RE
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20ASTRAZENECA : Touts Positive Survival Data for Cancer Therapies Imfinzi, Enhertu
MT
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Reduces Breast Cancer Death In Late-Stage Study
MT
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Shows 55% Tumor Response Rate in Lung Cancer Patien..
MT
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Prolongs Survival in Mid-Stage Gastric Cancer Study
MT
09/18DAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
09/21Le Nikkei 225 chute de 2,2 % en raison des perspectives immobilières en Chine
09/20AstraZeneca présente des données positives sur la survie des traitements anticancéreux ..
09/20Le médicament Enhertu d'AstraZeneca-Daiichi Sankyo réduit le nombre de décès dus au can..
09/20Le médicament Enhertu d'AstraZeneca-Daiichi Sankyo présente un taux de réponse tumorale..
09/20Enhertu d'AstraZeneca-Daiichi Sankyo prolonge la survie dans une étude sur le cancer ga..
09/16DPA-AFX ÜBERBLICK : KONJUNKTUR vom 16.09.2021 - 17.00 Uhr
09/16IAEA hebt erstmals seit Fukushima Prognose für Atomenergie an
09/13DEFENCE THERAPEUTICS INC. : Health Europa berichtet über Defence Therapeutics: Die Accum-T..
09/07Uravan Minerals augmente de 20 % alors qu'elle étudie des alternatives stratégiques en ..
08/20Le Nikkei 225 recule de 1% en raison des perspectives de Toyota et de la pandémie.
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
2019AstraZeneca raises sales forecast after second quarter cancer drug, China boost
RE
More recommendations
Press releases
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/18DAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
08/19Defence therapeutics selects the best 8 accumtm variants to optimize its adc therapeuti..
AQ
More press releases
Upcoming event on DAIICHI SANKYO COMPANY, LIMITED
09/29/21